BioNTech Historical Balance Sheet

BNTX Stock

USD 113.13 4.90 4.53%

Trend analysis of BioNTech SE balance sheet accounts such as Total Assets of 24.2 B, Short and Long Term Debt Total of 162.4 M or Other Current Liab of 744.1 M provides information on BioNTech's total assets, liabilities, and equity, which is the actual value of BioNTech SE to its prevalent stockholders. By breaking down trends over time using BioNTech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining BioNTech SE latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioNTech SE is a good buy for the upcoming year.

BioNTech Inventory

190.93 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About BioNTech Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of BioNTech SE at a specified time, usually calculated after every quarter, six months, or one year. BioNTech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BioNTech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BioNTech currently owns. An asset can also be divided into two categories, current and non-current.

BioNTech Balance Sheet Chart

At this time, BioNTech's Other Assets are fairly stable compared to the past year. Cash And Short Term Investments is likely to rise to about 17.4 B in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 162.4 M in 2024.

Accumulated Amortization Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Other Current Assets

Add Fundamental

Accumulated Amortization

The cumulative amount of amortization expense charged against intangible assets, like patents and copyrights, over time.

Total Assets

Total assets refers to the total amount of BioNTech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BioNTech SE books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on BioNTech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioNTech SE are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from BioNTech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	301.5M	212.2M	219.1M	162.4M
Total Assets	15.8B	23.3B	23.0B	24.2B

Short Long Term Debt Total Total Assets

BioNTech balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.76	0.87	0.85	1.0	0.98	0.62	-0.93	0.99	0.94	0.94	0.88	0.74	0.94	0.69	0.82	0.64	0.76	0.62	0.87	0.64	0.86	0.75	0.97	1.0	0.14
Short Long Term Debt Total	0.76		0.86	0.88	0.73	0.77	0.76	-0.58	0.68	0.73	0.58	0.59	0.39	0.57	0.78	0.53	0.82	0.43	0.57	0.87	0.83	0.89	0.4	0.74	0.76	0.56
Other Current Liab	0.87	0.86		0.97	0.85	0.8	0.44	-0.77	0.82	0.71	0.76	0.56	0.33	0.69	0.87	0.46	0.66	0.36	0.47	0.97	0.69	0.96	0.35	0.76	0.89	0.2
Total Current Liabilities	0.85	0.88	0.97		0.82	0.78	0.46	-0.68	0.79	0.7	0.67	0.56	0.34	0.63	0.94	0.47	0.67	0.38	0.55	1.0	0.61	1.0	0.36	0.75	0.88	0.14
Total Stockholder Equity	1.0	0.73	0.85	0.82		0.98	0.62	-0.95	1.0	0.95	0.95	0.9	0.76	0.95	0.65	0.83	0.63	0.78	0.61	0.85	0.63	0.84	0.78	0.97	0.99	0.13
Property Plant And Equipment Net	0.98	0.77	0.8	0.78	0.98		0.75	-0.93	0.98	0.98	0.94	0.94	0.81	0.96	0.58	0.88	0.69	0.82	0.64	0.8	0.72	0.8	0.82	0.99	0.97	0.27
Current Deferred Revenue	0.62	0.76	0.44	0.46	0.62	0.75		-0.53	0.6	0.8	0.55	0.79	0.72	0.63	0.27	0.79	0.69	0.74	0.62	0.46	0.8	0.49	0.72	0.77	0.59	0.74
Net Debt	-0.93	-0.58	-0.77	-0.68	-0.95	-0.93	-0.53		-0.95	-0.88	-1.0	-0.86	-0.72	-0.98	-0.44	-0.78	-0.55	-0.72	-0.49	-0.71	-0.64	-0.69	-0.74	-0.91	-0.92	-0.13
Retained Earnings	0.99	0.68	0.82	0.79	1.0	0.98	0.6	-0.95		0.95	0.96	0.91	0.78	0.97	0.61	0.85	0.59	0.8	0.62	0.82	0.6	0.81	0.8	0.97	0.99	0.09
Accounts Payable	0.94	0.73	0.71	0.7	0.95	0.98	0.8	-0.88	0.95		0.9	0.98	0.88	0.94	0.5	0.94	0.68	0.9	0.7	0.73	0.68	0.73	0.89	0.99	0.92	0.28
Cash	0.94	0.58	0.76	0.67	0.95	0.94	0.55	-1.0	0.96	0.9		0.87	0.74	0.98	0.44	0.8	0.55	0.75	0.49	0.71	0.64	0.68	0.76	0.92	0.93	0.14
Non Current Assets Total	0.88	0.59	0.56	0.56	0.9	0.94	0.79	-0.86	0.91	0.98	0.87		0.96	0.94	0.33	0.99	0.57	0.97	0.7	0.6	0.6	0.59	0.97	0.96	0.85	0.24
Non Currrent Assets Other	0.74	0.39	0.33	0.34	0.76	0.81	0.72	-0.72	0.78	0.88	0.74	0.96		0.85	0.13	0.99	0.39	1.0	0.7	0.39	0.42	0.39	1.0	0.86	0.69	0.14
Cash And Short Term Investments	0.94	0.57	0.69	0.63	0.95	0.96	0.63	-0.98	0.97	0.94	0.98	0.94	0.85		0.39	0.89	0.55	0.85	0.58	0.67	0.62	0.65	0.86	0.96	0.92	0.15
Net Receivables	0.69	0.78	0.87	0.94	0.65	0.58	0.27	-0.44	0.61	0.5	0.44	0.33	0.13	0.39		0.25	0.52	0.17	0.37	0.91	0.38	0.92	0.15	0.55	0.72	0.0
Good Will	0.82	0.53	0.46	0.47	0.83	0.88	0.79	-0.78	0.85	0.94	0.8	0.99	0.99	0.89	0.25		0.49	0.99	0.73	0.51	0.54	0.51	0.99	0.92	0.78	0.24
Common Stock Total Equity	0.64	0.82	0.66	0.67	0.63	0.69	0.69	-0.55	0.59	0.68	0.55	0.57	0.39	0.55	0.52	0.49		0.42	0.35	0.66	0.7	0.67	0.4	0.67	0.63	0.44
Short Term Investments	0.76	0.43	0.36	0.38	0.78	0.82	0.74	-0.72	0.8	0.9	0.75	0.97	1.0	0.85	0.17	0.99	0.42		0.72	0.43	0.43	0.43	1.0	0.87	0.71	0.16
Non Current Liabilities Total	0.62	0.57	0.47	0.55	0.61	0.64	0.62	-0.49	0.62	0.7	0.49	0.7	0.7	0.58	0.37	0.73	0.35	0.72		0.6	0.52	0.61	0.7	0.68	0.6	0.23
Inventory	0.87	0.87	0.97	1.0	0.85	0.8	0.46	-0.71	0.82	0.73	0.71	0.6	0.39	0.67	0.91	0.51	0.66	0.43	0.6		0.61	1.0	0.41	0.77	0.9	0.12
Other Current Assets	0.64	0.83	0.69	0.61	0.63	0.72	0.8	-0.64	0.6	0.68	0.64	0.6	0.42	0.62	0.38	0.54	0.7	0.43	0.52	0.61		0.62	0.43	0.68	0.63	0.8
Total Liab	0.86	0.89	0.96	1.0	0.84	0.8	0.49	-0.69	0.81	0.73	0.68	0.59	0.39	0.65	0.92	0.51	0.67	0.43	0.61	1.0	0.62		0.41	0.77	0.89	0.15
Long Term Investments	0.75	0.4	0.35	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97	1.0	0.86	0.15	0.99	0.4	1.0	0.7	0.41	0.43	0.41		0.87	0.71	0.14
Property Plant And Equipment Gross	0.97	0.74	0.76	0.75	0.97	0.99	0.77	-0.91	0.97	0.99	0.92	0.96	0.86	0.96	0.55	0.92	0.67	0.87	0.68	0.77	0.68	0.77	0.87		0.95	0.25
Total Current Assets	1.0	0.76	0.89	0.88	0.99	0.97	0.59	-0.92	0.99	0.92	0.93	0.85	0.69	0.92	0.72	0.78	0.63	0.71	0.6	0.9	0.63	0.89	0.71	0.95		0.12
Non Current Liabilities Other	0.14	0.56	0.2	0.14	0.13	0.27	0.74	-0.13	0.09	0.28	0.14	0.24	0.14	0.15	0.0	0.24	0.44	0.16	0.23	0.12	0.8	0.15	0.14	0.25	0.12

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Short Long Term Debt Total	76.5M	240.2M	301.5M	212.2M	219.1M	162.4M
Other Current Liab	16.4M	487.6M	1.6B	2.1B	1.1B	744.1M
Total Current Liabilities	138.1M	606.0M	3.5B	3.0B	2.1B	1.3B
Total Stockholder Equity	493.5M	1.4B	11.9B	20.1B	20.2B	21.3B
Other Liab	205.6M	97.1M	109.7M	283.9M	326.5M	166.9M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Property Plant And Equipment Net	148.1M	326.0M	520.4M	821.1M	971.6M	1.0B
Current Deferred Revenue	93.6M	391.5M	189.1M	77.1M	353.3M	371.0M
Net Debt	(450.2M)	(970.0M)	(1.4B)	(13.7B)	(11.4B)	(10.9B)
Retained Earnings	(424.8M)	(409.6M)	9.9B	18.8B	19.8B	20.8B
Accounts Payable	20.5M	102.3M	160M	204.1M	354M	371.7M
Cash	519.1M	1.2B	1.7B	13.9B	11.7B	12.2B
Non Current Assets Total	237.5M	651.7M	758.5M	1.4B	3.5B	3.7B
Non Currrent Assets Other	2K	1.0M	800K	6.5M	187.1M	196.5M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Long Term Debt	68.9M	231.0M	171.6M	176.2M	191M	116.1M
Cash And Short Term Investments	520.8M	1.3B	2.1B	14.1B	16.5B	17.4B
Net Receivables	20.2M	166.4M	12.4B	7.1B	2.3B	3.0B
Good Will	3.0M	53.7M	57.8M	61.2M	362.5M	380.6M
Common Stock Total Equity	166.8M	193.3M	232.3M	246.3M	283.3M	185.2M
Common Stock Shares Outstanding	211.5M	248.5M	259.7M	249.8M	242.7M	229.1M
Short Term Investments	1.7M	137.2M	381.6M	189.4M	4.9B	5.1B
Liabilities And Stockholders Equity	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Non Current Liabilities Total	166.0M	340.8M	455.5M	272.9M	689.9M	378.2M
Inventory	11.7M	64.1M	502.5M	439.6M	357.7M	190.9M
Other Current Assets	1.2M	392.6M	113.8M	272.3M	280.9M	146.4M
Other Stockholder Equity	(5.5M)	1.8B	(3.8M)	(5.3M)	(10.8M)	(10.3M)
Total Liab	304.2M	946.8M	3.9B	3.2B	2.8B	1.7B
Property Plant And Equipment Gross	148.1M	326.0M	594.6M	821.1M	1.2B	1.2B
Total Current Assets	560.2M	1.7B	15.1B	21.9B	19.5B	20.5B
Accumulated Other Comprehensive Income	691.5M	25.5M	1.8B	979.3M	244.8M	232.6M
Short Term Debt	7.6M	15.2M	129.9M	36M	56.2M	37.6M
Intangible Assets	86.5M	109.8M	144.6M	158.5M	781.7M	820.8M
Common Stock	232.3M	246.3M	246.3M	248.6M	285.9M	218.0M
Property Plant Equipment	116.0M	148.1M	326.0M	520.4M	598.5M	628.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Historical Balance Sheet

BioNTech Inventory

190.93 Million

About BioNTech Balance Sheet Analysis

BioNTech Balance Sheet Chart

Accumulated Amortization

Total Assets

Total Current Liabilities

Other Current Assets

BioNTech balance sheet Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech balance sheet Accounts

Also Currently Popular

Additional Tools for BioNTech Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Inventory	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Retained Earnings	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Non Currrent Assets Other

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Retained Earnings	- 0.95	Net Debt
Net Debt	- 0.95	Total Stockholder Equity
Net Debt	- 0.93	Property Plant And Equipment Net
Net Debt	- 0.93	Total Assets